Hypersensitivity Pneumonitis Market Trends

Growth Drivers

Rising Environmental Pollution – It is expected that rise in the release of harmful gases and chemicals into the air is anticipated to drive the growth of hypersensitivity pneumonitis market. Moreover, hypersensitivity pneumonitis is a long illness that is caused by an allergic reaction to certain substances (allergens) inhaled through the air.
According to estimates, more than 6 million people die from air pollution-related causes worldwide each year.
Growing Geriatric Population- Hypersensitivity pneumonitis (HP) is a complex interstitial lung disease (ILD) that is more common among those older than 65 years owing to weekend immune response, and the rising count of older people across the globe is estimated to drive market growth.
Lately, the number of individuals over 65 in the globe is more than 8% of the population, and this percentage is anticipated to increase to over 15% of the global population by 2050.

Challenges

Lack of Awareness – Owing to the absence of sufficient resources in low economic areas people the knowledge about prescription drugs such as corticosteroids is poor. This may impact the market growth as without proper knowledge this medication can be misused.
Risk Associated with Underdiagnosis and Misdiagnosis of Hypersensitivity Pneumonitis
Side Effects Associated with Long-Term Treatment

Hypersensitivity Pneumonitis Market: Key Insights

Base Year	2022
Forecast Year	2023-2035
CAGR	~6%
Base Year Market Size (2022)	~ USD 1 Billion
Forecast Year Market Size (2035)	~ USD 2 Billion
Regional Scope	North America (U.S., and Canada) Latin America (Mexico, Argentina, Rest of Latin America) Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific) Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe) Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Frequently Asked Questions (FAQ)

Increasing prevalence of respiratory diseases across the globe and the development of non-invasive diagnostic procedures are the major factors driving the growth of the market.

The market size of Hypersensitivity Pneumonitis is anticipated to attain a CAGR of 6% over the forecast period, i.e., 2023 â€“ 2035.

The major players in the market are Svizera Healthcare Pvt. Ltd., Sanofi S.A., Novo Nordisk A/S, Astra Zeneca Plc., Eli lilly and Company, Bayer AG, Sun Pharmaceutical Industries Ltd., Novartis AG.

The corticosteroids segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.

The market in the North American region is projected to hold the largest market share by the end of 2035 and provide more business opportunities in the future.

Hypersensitivity Pneumonitis Market Trends